Reslizumab for Pediatric Eosinophilic Esophagitis

• Assa‘ad A : Eosinophilic esophagitis: association with allergic disorders.Gastrointest. Endosc. Clin. N. Am.18 , 119–132 (2008).
   Google Scholar
• Roy-Ghanta S , LarosaDF, KatzkaDA: Atopic characteristics of adult patients with eosinophilic esophagitis.Clin. Gastroenterol. Hepatol.6 , 531–535 (2008).
   PubMed Web of Science ®Google Scholar
• Plaza-Martin AM , Jimenez-FeijooR, AndaluzCet al.: Polysensitization to aeroallergens and food in eosinophilic esophagitis in a pediatric population.Allergolog. Immunopathol.35 , 35–37 (2007).
   PubMed Web of Science ®Google Scholar
• Sugnanam KK , CollinsJT, SmithPKet al.: Dichotomy of food and inhalant allergen sensitization in eosinophilic esophagitis.Allergy62 , 1257–1260 (2007).
   PubMed Web of Science ®Google Scholar
• De Angelis P , MorinoG, PaneAet al.: Eosinophilic esophagitis: management and pharmacotherapy.Exp. Opin. Pharmacother.9 , 731–740 (2008).
   Web of Science ®Google Scholar
• Blanchard C , WangN, StringerKFet al.: Eotaxin-3 and a uniquely conserved gene-expression profile in eosinophilic esophagitis.J. Clin. Invest.116 , 536–547 (2006).
   PubMed Web of Science ®Google Scholar
• Straumann A , BauerM, FischerB, BlaserK, SimonHU: Idiopathic eosinophilic esophagitis is associated with a T(H)2-type allergic inflammatory response.J. Allergy Clin. Immunol.108 , 954–961 (2001).
   PubMed Web of Science ®Google Scholar
• Mishra A , RothenbergME: Intratracheal IL-13 induces eosinophilic esophagitis by an IL-5, eotaxin-1, and STAT6-dependent mechanism.Gastroenterology125 , 1419–1427 (2003).
   PubMed Web of Science ®Google Scholar
• Mishra A , HoganSP, BrandtEB, RothenbergME: An etiological role for aeroallergens and eosinophils in experimental esophagitis.J. Clin. Invest.107 , 83–90 (2001).
   PubMed Web of Science ®Google Scholar
• Blanchard C , RothenbergME: Basic pathogenesis of eosinophilic esophagitisGastrointest. Endosoc. Clin. N. Am.18 , 133–143 (2008).
   PubMedGoogle Scholar
• Oh HE , ChettyR: Eosinophilic gastroenteritis.J. Gastroenterol.43 , 741–750 (2008).
   PubMed Web of Science ®Google Scholar
• Liacouras CA : Pharmacologic treatment of eosinophilic esophagitis.Gastrointest. Endosc. Clin. N. Am.18 , 169–178 (2008).
   PubMedGoogle Scholar
• Walsh GM : Advances in the immunobiology of eosinophils and their role in disease.Crit. Rev. Clin. Lab. Sci.36 5453–496 (1999).
   Web of Science ®Google Scholar
• Blanchard C , RothenbergME: Biology of the eosinophil.Adv. Immunol.101 , 81–121 (2009).
   PubMed Web of Science ®Google Scholar
• Foster PS , HoganSP, RamsayAJ, MatthaeiKI, YoungIG: Interleukin 5 deficiency abolishes eosinophilia, airways hyperreactivity, and lung damage in a mouse asthma model.J. Exp. Med.183 , 195–201 (1996).
   PubMed Web of Science ®Google Scholar
• Iwamoto T , TakatsuK: Evaluation of airway hyperreactivity in interleukin-5 transgenic mice.Int. Arch. Allergy Immunol.1(Suppl.) , 28–30 (1995).
   Google Scholar
• Kay AB , KlionAD: Anti-interleukin-5 therapy for asthma and hypereosinophilic syndrome.Immunol. Allergy Clin. North Am.24 , 645–666 (2004).
   PubMed Web of Science ®Google Scholar
• Bullock JZ , VillanuevaJM, BlanchardCet al.: Interplay of adaptative Th2 immunity with eotaxin-3 C-C chemokine receptor 3 in eosinophilic esophagitis.J. Pediatr. Gastroenterol. Nutr.45 , 22–31 (2007).
   PubMed Web of Science ®Google Scholar
• Blanchard C , WangN, StringerKFet al.: Eotaxin-3 and a uniquely conserved gene-expression profile in eosinophilic esophagitis.J. Clin. Invest.116 , 536–547 (2006).
   PubMed Web of Science ®Google Scholar
• Liu LY , SedgwickJB, BatesMEet al.: Decreased expression of membrane IL-5 receptor alpha on human eosinophils: I. Loss of membrane IL-5 receptor alpha on airway eosinophils and increased soluble IL-5 receptor α in the airway after allergen challenge.J. Immunol.169 , 6452–6458 (2002).
   PubMed Web of Science ®Google Scholar
• Liu LY , SedgwickJB, BatesMEet al.: Decreased expression of membrane IL-5 receptor alpha on human eosinophils: II. IL-5 down-modulates its receptor via a proteinase-mediated process.J. Immunol.169 , 6459–6466 (2002).
   PubMed Web of Science ®Google Scholar
• Gevaert P , BachertC, HoltappelsGet al.: Enhanced soluble interleukin-5 receptor alpha expression in nasal polyposis.J. Allergy58 , 371–379 (2003).
   Google Scholar
• Egan RW , AthwalD, BodmerMWet al.: Effect of Sch 55700, a humanized monoclonal antibody to human interleukin-5, on eosinophilic responses and bronchial hyperreactivity.Arzneimittelforschung49(9) , 779–790 (1999).
   PubMed Web of Science ®Google Scholar
• Egan RW , AthwahlD, Chou C-C et al.: Inhibition of pulmonary eosinophilia and hyperreactivity by antibodies to interleukin-5. Int. Arch. Allergy Immunol.107 , 321–322 (1995).
   PubMed Web of Science ®Google Scholar
• Cook WJ , WalterLJ, MurgoloNJet al.: Structure and humanization of a rat monoclonal Fab to human interleukin-5.Protein Eng.9 , 623–628 (1996).
   Google Scholar
• Walsh GM : Mepolizumab and eosinophil-mediated disease.Curr. Med. Chem.16 , 4774–4778 (2009).
   PubMed Web of Science ®Google Scholar
• Kips JC , O‘ConnorBJ, LangleySJet al.: Effect of SCH55700, a humanized anti-human interleukin-5 antibody, in severe persistent asthma: a pilot study.Am. J. Resp. Crit. Care Med.167 , 1655–1659 (2003).
   PubMed Web of Science ®Google Scholar
• Walsh GM : Reslizumab, a humanized anti-IL-5 mAb for the treatment of eosinophil-mediated inflammatory conditions.Curr. Opin. Mol. Ther.11(3) , 329–336 (2009).
   PubMedGoogle Scholar
• Prussin C , JamesSP, HuberMM, KlionAD, MetcalfeDD: Pilot study of anti-IL-5 in eosinophilic gastroenteritis.J. Allergy Clin. Immunol.111(Suppl. 2) , S275 (2003).
   Google Scholar
• Straumann A , ConusS, GrzonkaPet al.: Anti-interleukin-5 antibody treatment (mepolizumab) in active eosinophilic oesophagitis: a randomised, placebo-controlled, double-blind trial.Gut59(1) , 21–30 (2010).
   PubMed Web of Science ®Google Scholar
• Collins PD , MarleauS, Griffiths-JohnsonDA, JosePJ, WilliamsTJ: Cooperation between interleukin-5 and the chemokine eotaxin to induce eosinophil accumulation in vivo.J. Exp. Med.182(4) , 1169–1174 (1995).
   PubMed Web of Science ®Google Scholar
• Gevaert P , Lang-LoidoltD, LacknerAet al.: Nasal IL-5 levels determine the response to anti-IL-5 treatment in patients with nasal polyps.J. Allergy Clin. Immunol.118 , 1133–1141 (2006).
   PubMed Web of Science ®Google Scholar
• Kim YJ , PrussinC, MartinBet al.: Rebound eosinophilia after treatment of hypereosinophilic syndrome and eosinophilic gastroenteritis with monoclonal anti-IL-5 antibody SCH55700.J. Allergy Clin. Immunol.114 , 1449–1455 (2004).
   PubMed Web of Science ®Google Scholar
• Nair P , PizzichiniMM, KjarsgaardMet al.: Mepolizumab for prednisone-dependent asthma with sputum eosinophilia.N. Engl. J. Med.360 , 985–993 (2009).
   PubMed Web of Science ®Google Scholar
• Haldar P , BrightlingCE, HargadonBet al.: Mepolizumab and exacerbations of refractory eosinophilic asthma.N. Engl. J. Med.360 , 973–984 (2009).
   PubMed Web of Science ®Google Scholar

▪ Websites

• NCT00587288: Efficacy and safety of reslizumab to treat poorly controlled asthma Ception Therapeutics Inc. (2009) www.clinicaltrials.gov
   Google Scholar
• Ception Therapeutics initiates Phase II/III clinical trial for its lead product reslizumab in eosinophilic esophagitis (EE) in children. Ception Therapeutics Inc. Press release, 5 March 2008 www.medicalnewstoday.com/articles/171907.php
   Google Scholar